Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ALCYONE Paves Way For J&J/Genmab's Darzalex In Frontline Myeloma

Executive Summary

Data supporting a role for J&J/Genmab's anti-CD38 monoclonal antibody in newly diagnosed multiple myeloma are "as good as could be expected," but the backbone regimen in the trial is rarely used in the US.


Related Content

At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise
Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights
Pharma Q3 Results Preview: J&J, Roche Set The Scene
Pharma Q3 Results Preview: J&J, Roche Set The Scene
Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?
Darzalex Setback In NHL Raises Stakes For First-Line Myeloma Approval
Myeloma Survival Benefit May Help Amgen's Kyprolis Stave Off Competition
Another Sea Change In Myeloma Promised By New Therapies, Combos


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts